Related references
Note: Only part of the references are listed.Pharmacokinetics and Imaging of 212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients
Ruby F. Meredith et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series
G. Suliman et al.
APPLIED RADIATION AND ISOTOPES (2013)
Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
Johnnie J. Orozco et al.
BLOOD (2013)
212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
K. J. Yong et al.
BRITISH JOURNAL OF CANCER (2013)
Comparison of 211At-PRIT and 211At-RIT of Ovarian Microtumors in a Nude Mouse Model
Sofia H. L. Frost et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
Production of [211At]-Astatinated Radiopharmaceuticals and Applications in Targeted α-Particle Therapy
Francois Guerard et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
Evaluation of Platinum Chemotherapy in Combination with HER2-Targeted α-Particle Radiation
Diane E. Milenic et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2013)
Chromatin Remodeling at DNA Double-Strand Breaks
Brendan D. Price et al.
CELL (2013)
Molecular Pathways: Targeted α-Particle Radiation Therapy
Kwamena E. Baidoo et al.
CLINICAL CANCER RESEARCH (2013)
Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer
Jorge A. Carrasquillo et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Radioimmunotherapy for hematopoietic cell transplantation
Joseph G. Jurcic
IMMUNOTHERAPY (2013)
Radioimmunotherapy for peritoneal cancers
Christof Seidl et al.
IMMUNOTHERAPY (2013)
General overview of radioimmunotherapy of solid tumors
Isabelle Navarro-Teulon et al.
IMMUNOTHERAPY (2013)
Differential gene expression in human fibroblasts after alpha-particle emitter 211At compared with 60Co irradiation
Anna Danielsson et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2013)
Sensitization of Tumor to 212Pb Radioimmunotherapy by Gemcitabine Involves Initial Abrogation of G2 Arrest and Blocked DNA Damage Repair by Interference With Rad51
Kwon Joong Yong et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Modifications in Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters After α-Particle-Emitting 227Th-trastuzumab Therapy of HER2-Expressing Ovarian Cancer Xenografts
Helen Heyerdahl et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma
Michel Cherel et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the α-Camera Technique
Nicolas Chouin et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: Radiolabeling, serum stability, and biodistribution and tumor uptake studies
Chi Soo Kang et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
Methodology for labeling proteins and peptides with lead-212 (212Pb)
Kwamena E. Baidoo et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator Radiotherapy
Mark F. McLaughlin et al.
PLOS ONE (2013)
Alpha-Particle Emitting 213Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
Christian Wulbrand et al.
PLOS ONE (2013)
Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb
Vincent Boudousq et al.
PLOS ONE (2013)
Histone Modifications and DNA Double-Strand Break Repair after Exposure to Ionizing Radiations
Clayton R. Hunt et al.
RADIATION RESEARCH (2013)
Targeted alpha-therapy using [Bi-213] anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells
Mareike Roscher et al.
ONCOTARGET (2013)
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211 At-mAb
Sophie E. Eriksson et al.
EJNMMI RESEARCH (2013)
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
Harrison et al.
Cancer Management and Research (2013)
DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy
Emil Mladenov et al.
FRONTIERS IN ONCOLOGY (2013)
Comparing High LET 227Th- and Low LET 177Lu-trastuzumab in Mice with HER-2 Positive SKBR-3 Xenografts
Nasir Abbas et al.
CURRENT RADIOPHARMACEUTICALS (2013)
Targeted Alpha Therapy with (227) Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice
Helen Heyerdahl et al.
CURRENT RADIOPHARMACEUTICALS (2013)
Treatment of Early and Established Cryptococcus neoformans Infection with Radiolabeled Antibodies in Immunocompetent Mice
Zewei Jiang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Measurement of the 226Th and 222Ra half-lives
S. Pomme et al.
APPLIED RADIATION AND ISOTOPES (2012)
Measurement of the 225Ac half-life
S. Pomme et al.
APPLIED RADIATION AND ISOTOPES (2012)
Measurement of the 230U half-life
S. Pomme et al.
APPLIED RADIATION AND ISOTOPES (2012)
Reagents for Astatination of Biomolecules. 6. An Intact Antibody Conjugated with a Maleimido-closo-Decaborate(2-) Reagent via Sulfhydryl Groups Had Considerably Higher Kidney Concentrations than the Same Antibody Conjugated with an Isothiocyanato-closo-Decaborate(2-) Reagent via Lysine Amines
D. Scott Wilbur et al.
BIOCONJUGATE CHEMISTRY (2012)
Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation
Yun Chen et al.
BLOOD (2012)
Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells
Kurtis J. Haro et al.
BLOOD (2012)
Evaluation of Effects on the Peritoneum After Intraperitoneal α-Radioimmunotherapy with 211At
Elin Cederkrantz et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2012)
Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest
Mario Vallon et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis
Markus Essler et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2012)
Orthotopic administration of 213Bi-bevacizumab inhibits progression of PC3 xenografts in the prostate
S. M. A. Rizvi et al.
IMMUNOTHERAPY (2012)
212Pb-Radioimmunotherapy Induces G2 Cell-Cycle Arrest and Delays DNA Damage Repair in Tumor Xenografts in a Model for Disseminated Intraperitoneal Disease
Kwon Joong Yong et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: The molecular choreography
Larry H. Thompson
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2012)
Toward Developing a Universal Treatment for Fungal Disease Using Radioimmunotherapy Targeting Common Fungal Antigens
R. A. Bryan et al.
MYCOPATHOLOGIA (2012)
Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model
Anna M. E. Gustafsson et al.
NUCLEAR MEDICINE AND BIOLOGY (2012)
High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum
Christian Rauch et al.
NUCLEAR MEDICINE AND BIOLOGY (2012)
Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
Nasir Abbas et al.
NUCLEAR MEDICINE COMMUNICATIONS (2012)
Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication
Ekaterina Dadachova et al.
PLOS ONE (2012)
Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting 227Th-DOTA-p-benzyl-trastuzumab
Helen Heyerdahl et al.
PLOS ONE (2012)
Bismuth-213 and Actinium-225 - Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes
Alfred Morgenstern et al.
CURRENT RADIOPHARMACEUTICALS (2012)
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
Michael F. Leahy et al.
BLOOD (2011)
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
John M. Pagel et al.
BLOOD (2011)
Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)
Damian Wild et al.
CANCER RESEARCH (2011)
Towards translation of Pb-212 as a clinical therapeutic; getting the lead in!
Kwon Yong et al.
DALTON TRANSACTIONS (2011)
177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi
Christof Seidl et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide
Eric Frampas et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma
Barry J. Allen et al.
IMMUNOTHERAPY (2011)
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody
J. Schwartz et al.
PHYSICS IN MEDICINE AND BIOLOGY (2011)
H2AX phosphorylation at the sites of DNA double-strand breaks in cultivated mammalian cells and tissues
Denis V. Firsanov et al.
CLINICAL EPIGENETICS (2011)
Experimental alpha-particle radioimmunotherapy of breast cancer using Th-227-labeled p-benzyl-DOTA-trastuzumab
Nasir Abbas et al.
EJNMMI RESEARCH (2011)
Astatine-211: Production and Availability
Michael R. Zalutsky et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Chemical and Radiochemical Considerations in Radiolabeling with alpha-Emitting Radionuclides
D. Scott Wilbur
CURRENT RADIOPHARMACEUTICALS (2011)
Applications of (211) At and Ra-223 in Targeted Alpha-Particle Radiotherapy
Ganesan Vaidyanathan et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Modelling and Dosimetry for Alpha-Particle Therapy
George Sgouros et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
David A. Scheinberg et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Patient-Specific Alpha-Particle Dosimetry
Stig Palm et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Targeted Alpha Therapy with Bi-213
Alfred Morgenstern et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Pretargeted Radioimmunotherapy with alpha-Particle Emitting Radionuclides
Sture Lindegren et al.
CURRENT RADIOPHARMACEUTICALS (2011)
The ARRONAX Project
Ferid Haddad et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates
Jostein Dahle et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Alpha-Particle Microdosimetry
Nicolas Chouin et al.
CURRENT RADIOPHARMACEUTICALS (2011)
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
Steven I. Park et al.
BLOOD (2010)
Anti-Prostate-Specific Membrane Antigen-Based Radioimmunotherapy for Prostate Cancer
Scott T. Tagawa et al.
CANCER (2010)
Improved Efficacy of α-Particle-Targeted Radiation Therapy
Diane E. Milenic et al.
CANCER (2010)
Immunoliposomal Delivery of 213Bi for α-Emitter Targeting of Metastatic Breast Cancer
Mohanambe Lingappa et al.
CANCER RESEARCH (2010)
Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to Tumors
Freddy E. Escorcia et al.
CANCER RESEARCH (2010)
Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
Todd L. Rosenblat et al.
CLINICAL CANCER RESEARCH (2010)
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate Th-227-rituximab
Jostein Dahle et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
D. Cordier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
In vitro experimental At-211-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin
Thorsten Petrich et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Differential gene expression triggered by highly cytotoxic α-Emitter-immunoconjugates in gastric cancer cells
Christof Seidl et al.
INVESTIGATIONAL NEW DRUGS (2010)
Radioimmunotherapy Is More Effective than Antifungal Treatment in Experimental Cryptococcal Infection
Ruth A. Bryan et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
George Sgouros et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Paradoxical glomerular filtration of carbon nanotubes
Alessandro Ruggiero et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Pilot Study of a 213Bismuth-Labeled Anti-CD45 mAb as a Novel Nonmyeloablative Conditioning for DLA-Haploidentical Littermate Hematopoietic Transplantation
Hirohisa Nakamae et al.
TRANSPLANTATION (2010)
Radioimmunotherapy Is Effective against High-Inoculum Cryptococcus neoformans Infection in Mice and Does Not Select for Radiation-Resistant Cryptococcal Cells
Ruth A. Bryan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Radiolabeled Antibodies to Bacillus anthracis Toxins Are Bactericidal and Partially Therapeutic in Experimental Murine Anthrax
Johanna Rivera et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Mutagenesis induced by targeted alpha therapy using 213Bi-cDTPA-9.2.27 in lacZ transgenic mice
Barry J. Allen et al.
CANCER BIOLOGY & THERAPY (2009)
Intraperitoneal Alpha-Radioimmunotherapy in Mice Using Different Specific Activities
Jorgen Elgqvist et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211
Hirohisa Nakamae et al.
CANCER RESEARCH (2009)
Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y
Hong Song et al.
CANCER RESEARCH (2009)
Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models BY 213Bilabeled Multiple Targeted α Radioimmunoconjugates
Yong Li et al.
CLINICAL CANCER RESEARCH (2009)
Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2-A Phase I Study
Hakan Andersson et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Intravesical α-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice
Birgit Pfost et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of α-particle-emitting 211At-labeled trastuzumab
Abraham Boskovitz et al.
NUCLEAR MEDICINE AND BIOLOGY (2009)
Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide 213Bi-DTPA-[F3]2 into the Nucleus of Tumor Cells
Enken Drecoll et al.
PLOS ONE (2009)
Radioimmunotherapy of human bladder cancer in a nude mouse model comparing Bi-213-anti-EGFR-MAb and Th-226-anti-EGFR-MAb
Birgit Pfost et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Production of 230U/226Th for Targeted Alpha Therapy via Proton Irradiation of 231Pa
Alfred Morgenstern et al.
ANALYTICAL CHEMISTRY (2008)
Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases
Min-Yuan Chang et al.
BIOCONJUGATE CHEMISTRY (2008)
213Bi (α-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model
Hong Song et al.
CANCER RESEARCH (2008)
Multimodality therapy: Potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease
Diane E. Milenic et al.
CLINICAL CANCER RESEARCH (2008)
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the α-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies
Matthew K. Robinson et al.
CLINICAL CANCER RESEARCH (2008)
Relative biologic effects of low-dose-rate α-emitting 227Th-rituximab and β-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation
Jostein Dahle et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Dongweon Song et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Clinical experience with alpha-particle-emitting At-211: Treatment of recurrent brain tumor patients with At-211-labeled chimeric antitenascin monoclonal antibody 81C6
Michael R. Zalutsky et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer
Sebastian Knoer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Treatment of Diffuse-Type Gastric Cancer Cells Using Bi-213-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination
Christof Seidl et al.
CURRENT RADIOPHARMACEUTICALS (2008)
Targeted α-particle radiotherapy with 211At-labeled monoclonal antibodies
Michael R. Zalutsky et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice
Stig Palm et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Radioimmunotherapy with α-particle -: Emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy
Marcus P. Kelly et al.
CLINICAL CANCER RESEARCH (2007)
Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate
Jostein Dahle et al.
BLOOD (2007)
213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe
Christof Seidl et al.
MOLECULAR CANCER THERAPEUTICS (2007)
213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice
Roswitha Beck et al.
CANCER SCIENCE (2007)
Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability
Roy H. Larsen et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma
Junping Cheng et al.
LARYNGOSCOPE (2007)
Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging
H. Matthias Buchhorn et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1
Meili Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Potentiation of high-LET radiation by gemcitabine: Targeting HER2 with trastuzumab to treat disseminated peritoneal disease
Diane E. Milenic et al.
CLINICAL CANCER RESEARCH (2007)
Selective Alpha-Particle Mediated Depletion of Tumor Vasculature with Vascular Normalization
Jaspreet Singh Jaggi et al.
PLOS ONE (2007)
Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells
Claudia Friesen et al.
CANCER RESEARCH (2007)
Targeted α-therapy:: past, present, future?
Martin W. Brechbiel
DALTON TRANSACTIONS (2007)
Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins
Ekaterina Dadachova et al.
PLOS MEDICINE (2006)
The anti-CD25 monoclonal antibody 7G7/B6, armed with the α-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia
Meili Zhang et al.
CANCER RESEARCH (2006)
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25
Zhuo Zhang et al.
BLOOD (2006)
Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P
Stefan Kneifel et al.
CLINICAL CANCER RESEARCH (2006)
In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines:: effect of specific activity and HER2 receptor heterogeneity on survival fraction
G Akabani et al.
NUCLEAR MEDICINE AND BIOLOGY (2006)
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission
RH Verheijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Initial evaluation of 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy
J Dahle et al.
NUCLEAR MEDICINE AND BIOLOGY (2006)
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Intralesional targeted alpha therapy for metastatic melanoma
BJ Allen et al.
CANCER BIOLOGY & THERAPY (2005)
Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody
S Bloechl et al.
CLINICAL CANCER RESEARCH (2005)
α-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2
DE Milenic et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Production of Ac-225 from Th-229 for targeted α therapy
C Apostolidis et al.
ANALYTICAL CHEMISTRY (2005)
In vitro characterization of 211At-labeled antibody A33 -: a potential therapeutic agent against metastatic colorectal carcinoma
Y Almqvist et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody
CM Richman et al.
CLINICAL CANCER RESEARCH (2005)
Cancer radioimmunotherapy with alpha-emitting nuclides
O Couturier et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death
C Seidl et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
Cyclotron production of Ac-225 for targeted alpha therapy
C Apostolidis et al.
APPLIED RADIATION AND ISOTOPES (2005)
A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro
T Nayak et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides
G Henriksen et al.
NUCLEAR MEDICINE AND BIOLOGY (2004)
Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the α-emitting radionuclides 212Bi or 211At
JN Wesley et al.
NUCLEAR MEDICINE AND BIOLOGY (2004)
Targeted alpha therapy in vivo:: direct evidence for single cancer cell kill using 149Tb-rituximab
GJ Beyer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2004)
Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody
D Milenic et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of α-emitting atomic nanogenerators targeting disialo-ganglioside GD2
M Miederer et al.
CLINICAL CANCER RESEARCH (2004)
Pretargeted α emitting radioimmunotherapy using 213Bi 1,4,7,10-tetraazacyclododecane-N,N′,N,N′-tetraacetic acid-biotin
ZS Yao et al.
CLINICAL CANCER RESEARCH (2004)
Selective T-cell ablation with bismuth-213-labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation
WA Bethge et al.
BLOOD (2003)
Experimental detection of α-particles from the radioactive decay of natural bismuth
P de Marcillac et al.
NATURE (2003)
Pretarget radiotherapy with an anti-CD25 antibody streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
ML Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts
BM Sandmaier et al.
BLOOD (2002)
Tumor therapy with targeted atomic nanogenerators
MR McDevitt et al.
SCIENCE (2001)
Share Paper
